News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , June 11, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June: Raymond James Life Sciences and MedTech Conference Tuesday,
View HTML
Toggle Summary ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights
-- Succession of topline data readouts expected, starting with Pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis in Q4 2019 -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif. , May 06, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.
View HTML
Toggle Summary ChemoCentryx to Hold First Quarter 2019 Financial Results Conference Call on Monday, May 6, 2019
MOUNTAIN VIEW, Calif. , April 29, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's first quarter 2019 financial results will be released after market close on Monday, May 6, 2019 . ChemoCentryx executive management will host a conference call and
View HTML
Toggle Summary ChemoCentryx to Present at the H.C. Wainwright Global Life Sciences Conference
MOUNTAIN VIEW, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019 at 9:10 a.m. BST .
View HTML
Toggle Summary ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors
MOUNTAIN VIEW, Calif. , March 28, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), announced today that, effective March 27, 2019 , Rita Jain , M.D., Senior Vice President and Chief Medical Officer of Akebia Therapeutics , has been appointed to the Company's Board of Directors. Dr.
View HTML
Toggle Summary ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
-- Strong Progress Across Company’s Orphan Disease Franchise of Novel Renal and Dermal Therapeutics -- -- Pivotal top-line data expected from ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA-associated  vasculitis, Q4 -- -- Launched AURORA clinical trial of avacopan in
View HTML
Toggle Summary ChemoCentryx to Hold Fourth Quarter 2018 Financial Results Conference Call on Monday, March 11, 2019
MOUNTAIN VIEW, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's fourth quarter 2018 financial results will be released after market close on Monday, March 11, 2019 . ChemoCentryx executive management will host a conference call
View HTML
Toggle Summary ChemoCentryx to Present at the 8th Annual SVB Leerink Global Healthcare Conference
MOUNTAIN VIEW, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 10:30 a.m.
View HTML
Toggle Summary ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorization (CMA) Application for ANCA-Associated Vasculitis in Europe; Phase III ADVOCATE Trial Data Release Planned for Q4 2019
-- Companies plan to file for full marketing approval to EMA and FDA in 2020 -- MOUNTAIN VIEW, Calif. and ZURICH, Switzerland, Jan. 24, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Ltd. , a company of Vifor Pharma Group , today announced that in light of
View HTML
Toggle Summary ChemoCentryx to Present at the 37th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 1:30 p.m. PST .
View HTML